The Clinical Development of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

The Clinical Development of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

PHA – August 2024

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study